Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-02-20
Target enrollment:
Participant gender:
Summary
Colorectal cancer of Mismatch Repair-proficient (pMMR)/ Microsatellite Stability (MSS)
accounts for approximately 85% of all colorectal cancer patients, which might be insensitive
to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Chemotherapy, such as CAPEOX regimen, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Celecoxib, a COX-2 inhibitor, can improve the immune
microenvironment and have a potential to synergy with immunotherapy. Chemotherapy can improve
the immunogenicity of cancer cells that might enhance the efficacy of immunotherapy. The aim
of this study is to explore whether chemotherapy and cyclooxygenase (COX) inhibitors combined
with anti-PD-1 monoclonal antibody (mAb) could improve efficacy for resectable colorectal
cancer patient with the pMMR/MSS phenotype.